{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:46:26Z","timestamp":1783734386338,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Letibotulinum toxin A (LeBA) was approved by the Ministry of Food and Drug Safety (known as the Korea Food &amp; Drug Administration) for cosmetic indications in 2012. However, the efficacy and safety of this newly introduced LeBA have not been investigated in crow's feet lines (CFL) treatment and standardization before its universal use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this multicentre, double\u2010blind, randomized, parallel, active\u2010controlled Phase III clinical trial with two stages (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier: NCT03408236) was to investigate the non\u2010inferiority of LeBA vs. the existing onabotulinum toxin A (OnBA) for the treatment of CFL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 240 subjects were randomized to either the test (LeBA) or control (OnBA) group. At the baseline and at weeks 4 while maximum smiling (primary efficacy assessment), 8, 12 and 16, investigator's on\u2010site evaluation, independent evaluator, evaluation by the subjects, subjects' satisfaction assessment and safety assessment were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 4, the response rate of primary efficacy assessment was 69.75% and 68.33% in the test (LeBA) and control (OnBA) groups, respectively, without a significant difference. Other minor secondary evaluation results showed significant differences suggesting that LeBA offered better improvement than OnBA, but the overall results did not show significant differences between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study showed that LeBA was as effective and safe as OnBA for the treatment of CFL at the same doses.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.17217","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T16:45:25Z","timestamp":1615826725000},"page":"1587-1594","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Randomized, double\u2010blind, active\u2010controlled, multicentre, phase III clinical trial with two stages to assess the safety and efficacy of letibotulinum toxin a vs. onabotulinum toxin a for subjects with moderate to severe crow's feet"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0137-6849","authenticated-orcid":false,"given":"K.H.","family":"Yoo","sequence":"first","affiliation":[{"name":"Department of Dermatology College of Medicine Chung\u2010Ang University Hospital Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-6401","authenticated-orcid":false,"given":"S.J.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Dermatology College of Medicine Chung\u2010Ang University Hospital Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3556-0740","authenticated-orcid":false,"given":"H.S.","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology College of Medicine Chung\u2010Ang University Hospital Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Won","sequence":"additional","affiliation":[{"name":"Department of Dermatology Asan Medical Center College of Medicine University of Ulsan Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.W.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology College of Medicine Konkuk University Hospital Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-7621","authenticated-orcid":false,"given":"B.J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology College of Medicine Chung\u2010Ang University Hospital Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2009.01261.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31070"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002669"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00482-2"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9080253"},{"key":"e_1_2_6_7_1","unstructured":"ClinicalTrials.gov [Internet].Identifier NCT01791920. To evaluate the safety and efficacy of Botulax\u00ae are not inferior to those of Botox\u00ae in the treatment of glabellar lines. URLhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01791920?term=NCT01791920&draw=2&rank=1(last accessed: 15 February 2013)."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.105567"},{"key":"e_1_2_6_9_1","first-page":"1291","article-title":"A prospective, neurophysiologic comparative study to assess the efficacy and duration of effect of incobotulinumtoxinA and abobotulinumtoxinA in the treatment of crow\u2019s feet","volume":"14","author":"Saybel A","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2017.1418013"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001920"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-017-0844-9"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000128"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S160723"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584780-000000000-00000"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124070"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e31818dbfe3"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000279377.86280.8d"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2016.1227989"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.90496"},{"key":"e_1_2_6_21_1","first-page":"73","article-title":"Atropine eye drops inappropriately used for diplopia following cosmetic botulinum A toxin injections","volume":"117","author":"Hagan JC","year":"2020","journal-title":"Mo Med Jan\u2010Feb"},{"key":"e_1_2_6_22_1","first-page":"942","article-title":"Diagnostic approach to diplopia","volume":"20","author":"Dinkin M","year":"2014","journal-title":"Continuum (Minneap Minn)"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492012000300014"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3341\/jkos.2015.56.5.799"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T09:06:11Z","timestamp":1692867971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/jdv.17217"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17217","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"assertion":[{"value":"2020-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}